Introduction
Helicobacter pylori (H. pylori) infection remains a major public health problem. Given the high resistance to antibiotics worldwide, quadruple regimens have emerged as first-line therapies for H. pylori infection, though their long-term consequences remain unclear.
Aims & Methods
Aim: This study aimed to evaluate major changes in the metabolic profile and body composition of patients submitted to H. pylori eradication using different quadruple therapies.
Methods: Patients were enrolled in a blind, randomized trial and assigned to one of five eradication regimens: A (Concomitant with metronidazole tid, 14 days); B (Concomitant with metronidazole bid, 14 days); C (Bismuth-containing Quadruple, 10 days); D (Sequential, 14 days); E (Hybrid, 14 days). Esomeprazole was the proton-pump inhibitor of choice. Efficacy, clinical safety, and metabolic changes including body composition by anthropometry and bioelectrical impedance analysis; lipid profile; glucose metabolism (glucose, insulin, glycohemoglobin, HOMA-IR); and systemic inflammation (ESR, CRP) were evaluated at 2- and 12-months post-treatment.
Results
A total of 233 patients completed the protocol (mean age 57.6±16.2 years; 52.8% males). Overall eradication and clinical adverse event rates were 97.9% and 53.6%, respectively. Following successful eradication, significant metabolic shifts were observed across all groups, including decreases in insulin and glycated hemoglobin (Z=4.04-5.12; p<0.03). Conversely, there was a significant increase in LDL-cholesterol, BMI, abdominal circumference, waist-to-hip ratio (WHR), total/visceral fat mass, and rates of obesity/visceral obesity (Z=4.33-13.05; p<0.03). Comparing the different treatment protocols, regimen B (Concomitant with metronidazole bid, 14 days) induced the most pronounced metabolic impact, significantly increasing WHR and total/visceral fat mass, compared to other therapies (Z=2.00-2.52; p<0.05). During follow-up, 37 patients (16.4%) experienced H. pylori recurrence, which was significantly associated with increased HDL-cholesterol and decreased fat-free mass (Z=2.26-6.95; p<0.05).
Conclusion
While quadruple therapies are highly effective for H. pylori eradication, they are associated with significant long-term metabolic and body composition shifts, most notably weight gain and increased visceral adiposity. The concomitant therapy with metronidazole bid was associated with the most pronounced worsening of anthropometric fat parameters. H. pylori recurrence tends to lead to a return to the metabolic profile observed prior to eradication. These findings highlight the potential need for metabolic surveillance and nutritional counseling following H. pylori eradication.
References
1. Zamani M , Ebrahimtabar F, et al. Systematic review with meta-analysis: the worldwide prevalence of Helicobacter pylori infection. Aliment Pharmacol Ther 2018;47(7):868-876.
2. Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut 2017;66(1):6-30.
3. Savoldi A, Carrara E, Graham DY, et al. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization Regions. Gastroenterology 2018;155(5):1372-1382.
4. Lopo I, Libânio D, Pita I, et al. Helicobacter pylori antibiotic resistance in Portugal: Systematic review and metaanalysis. Helicobacter 2018;23(4):e12493.
5. Bae SE, Choi KD, Choe J, et al. Effect of Helicobacter pylori Eradication on Metabolic Parameters and Body Composition including Skeletal Muscle Mass: A Matched Case-Control Study. Gut Liver. 2025;19(3):346-354.
6. Upala S, Sanguankeo A, Saleem SA, et al. Effects of Helicobacter pylori eradication on insulin resistance and metabolic parameters: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017;29(2):153-159.
7. Alavinejad P, Hajiani E, Parsi A, et al. Effect of Helicobacter pylori eradication on metabolic profile: an international, multicenter, case-control study. BMC Gastroenterol. 2022;22(1):507.
Disclosure
None of the authors have anything to declare with regard to personal or financial interests in carrying out this work.